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Ukraine, 40007 
THE ROLE OF VEGFA GENE POLYMORPHISM IN DIABETIC 
FOOT SYNDROME DEVELOPMENT. 
 
Introduction. The dysfunction of vascular endothelial growth factor 
A (VEGFA) is one of the leading factor of macro- and microangiopathy 
development in diabetic foot syndrome (DFS) patients. Recently, a num-
ber of experimental studies in various populations have been carried out 
to test the association between VEGFA gene polymorphisms and devel-
opment of chronic hyperglycemia vascular complications. At the same 
time, there are no such studies in Ukrainian population.  
Purpose. To check the possible association between C936T VEGFA 
gene polymorphism and DFS development in Ukrainian patients with 
type 2 diabetes mellitus (T2DM).  
Materials and methods. Venous blood of 154 patients with T2DM 
complicated by DFS and 124 individuals without diabetes and glucose 
intolerance was used. The polymerase chain reaction-restriction frag-
ment length polymorphism method (PCR-RFLP) was used for VEGFA 
C936T (rs3025039) polymorphism genotyping. Mathematical analysis of 
obtained data was performed using Statistical Package for Social Science 
software (SPSS, version 17.0, Chicago, IL, USA). 
Results. It was found that ratio of C/C-homozygotes, C/T-
heterozygotes and T/T-homozygotes (C936T VEGFA gene polymor-
phism) in patients with DFS was 47.4%, 41.6% and 11.0%; in the con-
trol group – 50.0%, 43.5%, 6.5%, respectively. Comparison of these 
genotypes frequencies between DFS patients and control subjects using 
χ2-Pearson criterion showed no significant difference (P = 0.413). The 
results of regression analysis under the dominant, recessive, superdomi-
nant and additive inheritance models also revealed no association be-
tween VEGFA C936T genotypes and DFS development (P > 0.05).  
Conclusion. There is no link between VEGFA C936T polymorphism 
and risk of DFS development in Ukrainian patients with T2DM. 
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РОЛЬ ГЕНЕТИЧНОГО ПОЛІМОРФІЗМУ VEGFA 
У РОЗВИТКУ СИНДРОМУ ДІАБЕТИЧНОЇ СТОПИ.  
  
Порушення функціонування судинного ендотеліального фактору 
росту А (VEGFA) є однією із причин розвитку мікро- та макроангі-
опатій під час синдрому діабетичної стопи (СДС) у пацієнтів із цу-
кровим діабетом. Останнім часом у різних популяціях світу вико-
нана низка експериментальних робіт щодо вивчення зв'язку генети-
чного поліморфізму VEGFA із розвитком судинних ускладнень 
хронічної гіперглікемії. При цьому в українській популяції такі ро-
боти відсутні. Метою даної роботи стало вивчення можливого 
зв'язку С936Т-поліморфізму гена VEGFA із розвитком СДС в украї-
нських пацієнтів із цукровим діабетом 2 типу (ЦД2).  
У роботі була використана венозна кров 154 хворих з ЦД2, 
ускладненого СДС, і 124 осіб без цукрового діабету і порушень то-
лерантності до глюкози. Для визначення поліморфізму С936Т 
(rs3025039) гена VEGFA була проведена полімеразна ланцюгова 
реакція з подальшим аналізом довжини рестрикційних фрагментів 
(PCR-RFLP). Статистичний аналіз був виконаний із використанням 
програми SPSS-17.  
У результаті було встановлено, що у хворих з СДС співвідно-
шення гомозигот СС, гетерозигот СТ і гомозигот ТТ за С936Т-
сайтом гена VEGFA склало 47,4%, 41,6% і 11,0%, а в контрольній 
групі – відповідно 50,0%, 43,5%, 6,5%. Порівняння частот зазначе-
них генотипів між пацієнтами з СДС і представниками групи кон-
тролю показало відсутність значущої різниці (Р = 0,413). Результати 
регресійного аналізу також не встановили зв'язку генотипів за 
С936Т-локусом гена VEGFA із розвитком СДС (P > 0,05). Отже, в 
українських пацієнтів із ЦД2 відсутній зв'язок між С936Т-
поліморфізмом гена VEGFA і ризиком розвитку СДС. 
Ключові слова: синдром діабетичної стопи, генетичний полі-
морфізм, VEGFA.  
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Introduction 
Diabetes mellitus complicated by diabetic foot 
syndrome (DFS) is of significant relevance in high-
ly developed countries of the world, as evidenced 
by the high level of fatal consequences, lower limb 
amputations and the place that DFS occupies 
among complex medical and social problems, re-
quiring significant intellectual, organizational and 
economic resources [1, 2]. 
DFS was first separated as an independent dis-
ease by the WHO research group on diabetes melli-
tus in Geneva in 1987. This syndrome complicates 
the course of diabetes mellitus in 4–25% of pa-
tients. In such case, the risk of lower limb gangrene 
in patients is 20 times higher than in the general 
population. Almost every minute an amputation 
caused by DFS is performed somewhere in the 
world. The percentage of postoperative complica-
tions in such patients reaches 37, and postoperative 
mortality is 9–26% [3]. 
Identification of genetic factors of type 2 diabe-
tes mellitus (DM2) is the most important part of 
research in the study of this pathology, since the 
identification of candidate genes for diabetes devel-
opment allows to shed much light on the pathogen-
esis of the disease, the mechanisms of its complica-
tions, the principles of diagnosis, personalized 
treatment and prevention [4]. 
Endothelial dysfunction is known to play an im-
portant role in the pathogenesis of DFS. It is be-
lieved that one of the factors of occurrence of mac-
ro- and microvascular complications in DFS could 
be represented by a dysfunction of vascular endo-
thelial growth factor A (VEGFA), which is a pow-
erful mitogen of endothelial cells of blood vessels 
and protein, which ensures the migration of endo-
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thelial cells, their invasion into the collagen gel and 
the formation of new blood vessels. In addition, 
VEGFA is necessary not only for the formation of 
normal vessels, but also for their maturation and 
survival [5]. The experiment shows that a long-term 
VEGFA concentration decrease or blockade leads 
to deterioration in the survival of endothelial cells, 
a decrease in the tissues of terminal arterioles and 
capillaries, and blood pressure increase [6]. 
The VEGFA gene is located on the short arm of 
chromosome 6 (6p21.3) and consists of 8 exons 
separated by 7 introns [7]. Today, according to ncbi 
website 
(https://www.ncbi.nlm.nih.gov/snp/?term=VEGFA), 
there are 4590 polymorphic sites in the VEGFA 
gene. One of the most clinically significant is the 
polymorphic locus C936T, which is located in the 
3'-nontranslated area (3'UTR) of the gene. In differ-
ent populations of the world it is shown that this 
polymorphic site is associated with the develop-
ment of DM2 and its complications [8 – 10]. How-
ever, there is no data on the relationship of this sin-
gle-nucleotide polymorphism with the development 
of DFS. 
Objective. Study of potential link of С936Т-
polymorphism of the VEGFA gene with the devel-
opment of DFS in Ukrainian patients with DM2. 
Materials and methods. The blood of 154 pa-
tients with DM2 complicated by diabetic foot syn-
drome, who were hospitalized to MI "Sumy City 
Clinical Hospital No. 5" in the departments of vas-
cular surgery and Department of Surgery No. 3 
during 2011-2013, was used in the work. DFS was 
diagnosed on the basis of the Order of the Ministry 
of Health of Ukraine No. 1118 dated 21.12.2012 
"On Approval and Implementation of Medical and 
Technological Documents on Standardization of 
Medical Care in Type 2 Diabetes Mellitus". As-
sessment of the condition of limbs included the 
detection of ulcers or amputations of the foot in 
history, symptoms of peripheral artery disease; de-
tection of skin color changes in the lower extremi-
ties; detection of deformities of the foot and review 
of shoes, identifying visible signs of neuropathy, 
the initial stages of ischemia, nail deformation or 
damage. Neurological status was assessed in ac-
cordance with the standards of diabetic neuropathy 
assessment. Assessment of arterial blood flow in-
cluded palpatory determination of its level and as-
sessment of the symmetry of pulsation on the ves-
sels of the lower extremities. Insufficiency of arte-
rial blood flow in the lower limbs was assessed 
according to Fontaine-Leriche-Pokrovsky classifi-
cation. Duplex ultrasound scanning of lower ex-
tremity arteries, rheovasography and angiographic 
examination were used as instrumental methods. 
Also, a bacteriological study of ulcerative exudate 
was conducted to determine the microflora and its 
sensitivity to antibacterial drugs. Laboratory studies 
included clinical analysis of blood and urine, de-
termination of blood glucose, glycemic profile, gly-
cosylated hemoglobin. 
The control group consisted of 124 people with-
out diabetes mellitus and impaired glucose toler-
ance. The absence of other multifactorial diseases 
was confirmed by collecting anamnestic data, elec-
trocardiogram, blood pressure measurements, and 
biochemical studies. The study was conducted in 
compliance with the main provisions of the Council 
of Europe Convention on Human Rights and Bio-
medicine, the Helsinki Declaration of the World 
Medical Association on ethical principles of scien-
tific medical research with human participation 
(1964, with subsequent amendments, including 
version as of 2000) and Order of the Ministry of 
Health of Ukraine No. 690 dated 23.09. 2009. Prior 
to venous blood sampling for genetic analysis all 
patients signed an informed consent. Blood sam-
pling for genotyping was performed under sterile 
conditions into 2.7 ml monovettes (Sarstedt, Ger-
many) containing potassium EDTA as anticoagu-
lant. Samples were frozen and stored at -20 ºC. 
DNA for genotyping was isolated from blood 
leukocytes using GeneJET Whole Blood Genomic 
DNA Purification Mini Kit (Thermo Fisher Scien-
tific, USA) according to the manufacturer's proto-
col. In order to determine С936Т polymorphism 
(rs3025039) of the VEGFA gene a polymerase 
chain reaction with subsequent analysis of the re-
striction fragment length (PCR-RFLP) was per-
formed. The VEGFA gene site containing polymor-
phic locus was amplified with a pair of specific 
primers: upstream (sense) – 5'-
AAGGAAGAGGAGACTCTGCGCAGAGC-3' 
and downstream (antisense) – 5'-
TAAATGTATGTATGTGGGTGGGTGTGTC-
TACAGG-3'. Primers were synthesized by Metabi-
on (Germany). For PCR, 50-100 ng of DNA was 
taken and added to a mixture, containing 5 µl of a 
5-fold PCR buffer, 1.5 mmol/l of magnesium sul-
fate, 200 µmol/l of a mixture of four nucleotide 
triphosphates, 15 pmol/l of each primer and 1 unit 
of Taq-polymerase (ThermoFisher Scientific, 
USA), the volume was adjusted to 25 µl with de-
ionized water. PCR was carried out in a thermal 
cycler GeneAmpPCR System 2700 (ThermoFisher 
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Scientific, USA). The amplification consisted of 33 
cycles: denaturation – 94°C (50 s), hybridization – 
59°C (60 s) and elongation – 72°C (60 s). For re-
striction analysis, 6 µl of the amplification product 
(208 pb) was incubated at 37°C for 18 h with the 
addition of 5 units of Hin1II restrictase (NlaIII) 
(ThermoFisher Scientific, USA). If +936
th
 position 
of 3'-untranslated region of the VEGFA gene con-
tained cytosine, endonuclease did not find re-
striction site and the original fragment 208 bp re-
mained unchanged. In case of cytosine to thymine 
replacement, Hin1II restrictase split the amplificate 
into two fragments – 122 bp and 86 bp. Restriction 
fragments were separated by electrophoresis on 
2.0% agarose gel containing ethidium bromide. 
After electrophoresis, DNA visualization was car-
ried out using transiluminator "Biocom".  
Statistical analysis was performed using SPSS-
17 program. Continuous data are presented as the 
mean value ± SD (standard deviation), nominal data 
are presented as quantitative and percentage values. 
Testing of continuous data on the normality of dis-
tribution was carried out using the Kolmogorov-
Smirnov test. Сomparison of the distribution of 
genotypes in the experimental and control groups 
and verification of the correspondence of this dis-
tribution to the Hardy-Weinberg equilibrium was 
performed using Pearson's χ2-criterion. In order to 
establish the risk of DFS development, the odds 
ratio (OR) and 95% confidence interval (CI) for 
dominant, recessive, superdominant and additive 
inheritance models were calculated. Such DM2 risk 
factors, like age, gender, BMI, smoking, obesity 
and arterial hypertension (AH) were used as a co-
variate during multivariable logistic regression 
analysis. All tests were two-sided, value of P < 0.05 
was considered statistically significant. 
Study results. Clinical characteristics of 154 
patients with DFS and 124 persons of the control 
group are presented in Table 1. No significant dif-
ference was found between the comparison groups 
in the indicators of mean diastolic blood pressure (P 
= 0.109), as well as in the ratio of smokers (P = 
0.173), persons with BMI > 25 kg/m
2 
(P = 0.060) 
and with AH (P = 0.1121). In this case, BMI (P = 
0.007) and blood glucose concentration (P < 0.001) 
in patients were significantly higher compared to 
the control group (P < 0.001), and systolic blood 
pressure (P < 0.001), on contrary, was higher in 
patients without DFS. Also, the comparison groups 
differed in the ratio of persons of different sexes (P 
= 0.038) and the presence of persons with obesity 
(P = 0.027). In addition, it should be noted that the 
average age of the control group representatives 
(76.6 ± 10.2 years) was significantly higher than in 
patients with DFS (P < 0.001). The latter circum-
stance increased the reliability of control, because 
the probability of the development of DM2 and its 
complications in these people in the future de-
creased. 
Table 1 – Сharacteristics of the patients with DFS and the controls 
Parameter 
DFS 
(n = 154) 
Control group 
(n = 124) 
P 
Age, years 64.7 ± 8.2 76.6 ± 10.2 < 0.001 
Sex, female/male 13/16 45/79 0.038 
BMI, kg/m
2
 29.3 ± 4.9 27.7 ± 4.9 0.007 
Systolic pressure, mm Hg 9.99 ± 6.96 152.8 ± 23.2 < 0.001 
Diastolic pressure, mm Hg 88.5 ± 9.6 86.4 ± 12.3 0.109 
Fasting glucose, mmol/L 10.2 ± 3.5 5.29 ± 0.7 < 0.001 
BMI > 25 kg/m
2
, n (%) 122 (79.2) 86 (69.4) 0.060 
Obesity, n (%) 59 (38.3) 32 (25.8) 0.027 
Smokers, n (%) 50 (32.5) 31 (25.0) 0.173 
Arterial hypertension, n (%) 108 (70.1) 76 (61.3) 0.121 
Notes: n – number of patients, DFS – diabetic foot syndrome, BMI – body mass index. Categorical variables 
were compared by means of χ2-test, continuous variables were compared by means of t-test 
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Table 2 presents the frequencies of the main (C) 
and minor (T) alleles and shows the distribution of 
genotypes in C936T-polymorphic site 3'UTR of the 
VEGFA gene in patients with DFS and representa-
tives of the control group. It is shown that the fre-
quencies of these genotypes in the control and ex-
perimental groups did not deviate from the Hardy-
Weinberg equilibrium (P > 0.05). Comparison of 
frequencies of three possible variants of genotypes, 
formed by polymorphic locus C936T of the VEGFA 
gene between patients with DFS and representatives 
of the control group showed no significant differ-
ence (P = 0.413). 
Table 2 – Frequency of alleles and genotypes of C936T polymorphism in the VEGFA gene in the groups 
compared 
 
DFS 
(n = 154) 
Control group 
(n = 124) 
Homozygotes СС, n (%) 73 (47.4) 62 (50.0) 
Heterozygotes СТ, n (%) 64 (41.6) 54 (43.5) 
Homozygotes ТТ, n (%) 17 (11.0) 8 (6.5) 
С-allele 0.68 0.72 
Т-allele 0.32 0.28 
χ2 0.27 0.69 
P > 0.05 > 0.05 
Notes: n – number of parients; DFS – diabetic foot syndrome; χ2 and P reflect deviations from Hardy-
Weinberg law in each group 
The results of the regression analysis of the 
relationship of genotypes based on C936T-
polymorphism of the VEGFA gene with the 
development of DFS in the framework of dominant, 
recessive, superdominant and additive inheritance 
models are shown in Table 3. The use of binary 
logistic regression did not reveal a reliable 
association of the studied locus with the 
development of DFS in any of the models (P > 
0.05). After that, the multivariable logistic 
regression was used. However, even after 
correction for age, sex, BMI, obesity, hypertension 
and smoking habits, a significant association of 
different genotypes by polymorphic locus 3'UTR of 
the VEGFA gene with the development of DFS 
could not be established (P > 0.05). 
Table 3 – Analysis of association between the C936T-polymorphism in the VEGFA gene and DFS in different in-
heritance models  
Модель Pobs ORobs (95% CI) Padj ORadj (95% CI) 
Dominant 0.667 1.110 (0.691-1.781) 0.743 1.085 (0.667-1.765) 
Recessive 0.189 1.799 (0.749-4.320) 0.218 1.761 (0.716-4.333) 
Super-dominant 0.739 0.922 (0.571-1.487) 0.701 0.908 (0.556-1.484) 
Additive* 
0.979 1.007 (0.613-1.653) 0.962 0.988 (0.594-1.643) 
0.201 1.805 (0.729-4.466) 0.239 1.751 (0.690-4.447) 
Note: 95% CI – 95% confidence interval; Pobs – observed P-value (not adjusted for covariates); ORobs – observed 
odds ration; Padj – observed P-value adjusted for age, sex, smoking status, BMI, obesity and AH status; ORadj – odds 
ration adjusted for covariates. 
а
The first line in the additive model reflects the comparison of the CT-genotype with the CC-genotype, the second 
line reflects the comparison of the TT-genotype with the CC-genotype. 
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Discussion of the results. Single nucleotide 
polymorphism of rs3025039 is a replacement of 
cytosine for thymine at the +936
th
 position of 3'-non-
translated portion of the VEGFA gene. Such single 
point replacement may prevent binding of the 
transcription factor AP-4 (transcription factor 
activating enhancer binding protein 4), which in turn 
can affect the qualitative and quantitative 
characteristics of the future mRNA [11]. According to 
this, the relation of 936T-locus of the VEGFA gene 
with a decrease in its expression and plasma protein 
concentration has been demonstrated [11, 12]. 
In recent years, a number of works, dedicated to 
studying the effect of rs3025039-polymorphism of 
the VEGFA gene on the development of DM2 and 
its complications, were carried out. Thus, Sellami et 
al. demonstrated connection of this locus with the 
development and duration of DM2 among the 
Tunisian population [9]. A group of Russian 
authors, Klimontov et al., established a connection 
of C936T-site with VEGFA concentration in blood 
plasma and development of coronary heart disease 
in patients with DM2 [8]. And the results of the 
meta-analysis, conducted by Han et al., 
demonstrated a strong connection of С936Т-
polymorphism of the VEGFA gene with the risk of 
diabetic retinopathy among the Chinese population 
[10]. 
Our study was the first one to conduct the 
analysis of the relationship of С936Т-polymorphic 
site of the VEGFA gene with the risk of DFS among 
the Ukrainian patients with DM2. Comparison of 
genotype frequencies at the specified locus between 
the patients of the experimental and control groups, 
as well as regression analysis with and without the 
correction for various risk factors of diabetes did 
not allow to establish link of C936T polymorphic 
site of the VEGFA gene with the development of 
DFS in the Ukrainian population. 
However, the works of several teams have 
already proved the connection of other polymorphic 
loci of the VEGFA gene with the development of 
DFS. Xiaolei et al. demonstrated the protective role 
of rs699947-locus of the VEGFA gene regarding 
the DFS development in Chinese patients [13]. Li et 
al. found a similar protective effect regarding the 
DFS development, as well as a link with the protein 
content in blood plasma for the polymorphic site G-
634C of the VEGFA gene [14]. Among the 
population of Iran, the link with the risk of DFS 
development for C-2578A polymorphism of of the 
VEGFA gene promoter was established [15]. 
It should be noted that a significant limitation of 
our study is the relatively small number of patients, 
included in the comparison groups. Thus, a possible 
association between the C936T-site and the risk of 
DFS could not be detected because of a small 
statistical force. Another limitation is the 
investigation of relationship between polymorphic 
locus and phenotype without assessing their effect 
on VEGFA mRNA content and its protein 
concentration in blood plasma. 
 
Conclusions  
Thus, the results of the study showed absence of 
relationship between C936T polymorphism of the 
VEGFA gene and the development of DFS among 
Ukrainian population. Both before and after 
correction for age, gender, smoking habit, body 
mass index, obesity, and hypertension, none of the 
genotypes were associated with the risk of DFS in 
patients with DM2. 
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